Table 2.
Approved combination strategies with the PD-1/PDL1 inhibitor.
| Combined strategy | anti−PD−1/PD−L1 | Cancer type | Clinical trial | Approval time |
|---|---|---|---|---|
| Chemotherapy | Pembrolizumab | Metastatic non-squamous NSCLC | KEYNOTE-189 (NCT02578680) | 08/20/2018 |
| Metastatic squamous NSCLC | KEYNOTE-407 (NCT02775435) | 10/30/2018 | ||
| Metastatic TNBC | KEYNOTE-355 (NCT02819518) | 11/13/2020 | ||
| Esophageal or GEJ carcinoma | KEYNOTE-590 (NCT03189719) | 03/22/2021 | ||
| Cervical cancer | KEYNOTE-826 (NCT03635567) | 10/13/2021 | ||
| Nivolumab | Metastatic gastric cancer and esophageal adenocarcinoma | CHECKMATE-649 (NCT02872116) | 04/16/2021 | |
| Atezolizumab | PD-L1 positive unresectable locally advanced or metastatic TNBC | IMpassion130 (NCT02425891) | 03/18/2019 | |
| ES-SCLC | IMpower133 (NCT02763579) | 03/18/2019 | ||
| Metastatic NSCLC without EGFR/ALK aberrations | IMpower130 (NCT02367781) | 12/03/2019 | ||
| Durvalumab | ES-SCLC | NCT03043872 | 03/27/2020 | |
| Axitinib | Pembrolizumab | Advanced RCC | KEYNOTE−426 (NCT02853331) | 04/19/2019 |
| Avelumab | RCC | JAVELIN Renal 101 (NCT02684006) | 05/14/2019 | |
| Lenvatinib | Pembrolizumab | Advanced endometrial carcinoma | KEYNOTE-775 (NCT03517449) | 06/21/2021 |
| Bevacizumab | Atezolizumab | Unresectable HCC | IMbrave150 (NCT03434379) | 05/29/2020 |
| Cabozantinib | Nivolumab | Advanced RCC | CHECKMATE-9ER (NCT03141177) | 01/22/2021 |
| Ipilimumab (anti-CTLA-4) | Nivolumab (anti-PD-1) | Metastatic melanoma | CheckMate-069 | 10/01/2015 |
| Intermediate- or poor-risk advanced RCC | CheckMate 214 (NCT02231749) | 04/16/2018 | ||
| MSI-H/dMMR colorectal cancer | CHECKMATE 142 (NCT02060188) | 07/10/2018 | ||
| HCC | CHECKMATE-040, (NCT01658878) | 03/10/2020 | ||
| PD-L1-positive NSCLC | CHECKMATE-227 (NCT02477826) | 05/15/2020 | ||
| Malignant pleural mesothelioma | CHECKMATE-743 (NCT02899299) | 10/02/2020 | ||
| Relatlimab (LAG-3 inhibitor) | Nivolumab | Unresectable or metastatic melanoma | RELATIVITY-047 (NCT03470922) | 03/18/2022 |
NSCLC, non-small cell lung cancer; TNBC, triple-negative breast cancer; GEJ, gastroesophageal; ES-SCLC, extensive-stage small cell lung cancer; RCC, renal cell carcinoma; HCC, hepatocellular carcinoma.